Uridine as a potentiator of aminoglycosides through activation of carbohydrate transporters
暂无分享,去创建一个
E. Denamur | Z. Baharoglu | M. Ingersoll | D. Mazel | Stéphane Renard | E. Bacqué | Manon Lang | A. Amoura | T. Brosschot | Imane El-Meouche
[1] E. Krin,et al. Identification of the active mechanism of aminoglycoside entry in V. cholerae through characterization of sRNA ctrR, regulating carbohydrate utilization and transport , 2023, bioRxiv.
[2] V. de Crécy-Lagard,et al. Queuosine modification of tRNA-Tyrosine elicits translational reprogramming and enhances growth of Vibrio cholerae with aminoglycosides , 2022, bioRxiv.
[3] E. Krin,et al. Nonessential tRNA and rRNA modifications impact the bacterial response to sub-MIC antibiotic stress , 2022, bioRxiv.
[4] G. Robinson,et al. Proton motive force underpins respiration-mediated potentiation of aminoglycoside lethality in pathogenic Escherichia coli , 2022, Archives of Microbiology.
[5] Alan D. Lopez,et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis , 2022, The Lancet.
[6] M. Shin,et al. DksA Modulates Antimicrobial Susceptibility of Acinetobacter baumannii , 2021, Antibiotics.
[7] E. Krin,et al. Interplay between Sublethal Aminoglycosides and Quorum Sensing: Consequences on Survival in V. cholerae , 2021, Cells.
[8] P. Bouloc,et al. A Small Regulatory RNA Generated from the malK 5′ Untranslated Region Targets Gluconeogenesis in Vibrio Species , 2021, mSphere.
[9] E. Krin,et al. Sleeping ribosomes: Bacterial signaling triggers RaiA mediated persistence to aminoglycosides , 2020, bioRxiv.
[10] Marco Piñón,et al. I Overview , 2020, The Diaries and Letters of Lord Woolton 1940-1945.
[11] K. Allison,et al. Potentiating aminoglycoside antibiotics to reduce their toxic side effects , 2020, PloS one.
[12] M. Winterhalter,et al. Kanamycin uptake into Escherichia coli is facilitated by OmpF and OmpC porin channels located in the outer membrane. , 2020, ACS infectious diseases.
[13] D. Fourmy,et al. Fluorescent aminoglycoside antibiotics and methods for accurately monitoring uptake by bacteria. , 2020, ACS infectious diseases.
[14] İ. Kurultak,et al. A New Artificial Urine Protocol to Better Imitate Human Urine , 2019, Scientific Reports.
[15] S. van Calenbergh,et al. Host metabolites stimulate the bacterial proton motive force to enhance the activity of aminoglycoside antibiotics , 2019, PLoS pathogens.
[16] G. Péhau-Arnaudet,et al. A peptide of a type I toxin−antitoxin system induces Helicobacter pylori morphological transformation from spiral shape to coccoids , 2019, Proceedings of the National Academy of Sciences.
[17] K. Mertens,et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis , 2019, The Lancet. Infectious diseases.
[18] K. Krause,et al. Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation. , 2018, EcoSal Plus.
[19] Sherie J Smith,et al. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. , 2018, The Cochrane database of systematic reviews.
[20] P. Plésiat,et al. Mutations in Gene fusA1 as a Novel Mechanism of Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa , 2017, Antimicrobial Agents and Chemotherapy.
[21] Dorival Martins,et al. Stimulating Central Carbon Metabolism to Re-sensitize Pseudomonas aeruginosa to Aminoglycosides. , 2017, Cell chemical biology.
[22] Samuel I. Miller. Antibiotic Resistance and Regulation of the Gram-Negative Bacterial Outer Membrane Barrier by Host Innate Immune Molecules , 2016, mBio.
[23] K. Krause,et al. Aminoglycosides: An Overview. , 2016, Cold Spring Harbor perspectives in medicine.
[24] Y. Seok,et al. HPr antagonizes the anti-σ70 activity of Rsd in Escherichia coli , 2013, Proceedings of the National Academy of Sciences.
[25] Juhyun Kim,et al. The Standard European Vector Architecture (SEVA): a coherent platform for the analysis and deployment of complex prokaryotic phenotypes , 2012, Nucleic Acids Res..
[26] N. Fujita,et al. Novel Roles of cAMP Receptor Protein (CRP) in Regulation of Transport and Metabolism of Carbon Sources , 2011, PloS one.
[27] James J. Collins,et al. Metabolite-Enabled Eradication of Bacterial Persisters by Aminoglycosides , 2011, Nature.
[28] M. Reed. Optimal Antibiotic Dosing , 2010 .
[29] Z. Baharoglu,et al. Conjugative DNA Transfer Induces the Bacterial SOS Response and Promotes Antibiotic Resistance Development through Integron Activation , 2010, PLoS genetics.
[30] E. Sonnleitner,et al. Small RNA as global regulator of carbon catabolite repression in Pseudomonas aeruginosa , 2009, Proceedings of the National Academy of Sciences.
[31] J. Blázquez,et al. The Glycerol-3-Phosphate Permease GlpT Is the Only Fosfomycin Transporter in Pseudomonas aeruginosa , 2009, Journal of bacteriology.
[32] Ling-Hui Li,et al. Genome Sequencing and Comparative Analysis of Klebsiella pneumoniae NTUH-K2044, a Strain Causing Liver Abscess and Meningitis , 2009, Journal of bacteriology.
[33] B. Görke,et al. Carbon catabolite repression in bacteria: many ways to make the most out of nutrients , 2008, Nature Reviews Microbiology.
[34] A. Clatworthy,et al. Targeting virulence: a new paradigm for antimicrobial therapy , 2007, Nature Chemical Biology.
[35] D. Andersson,et al. Compensatory evolution reveals functional interactions between ribosomal proteins S12, L14 and L19. , 2007, Journal of molecular biology.
[36] M. P. Gallagher,et al. The nucleoside transport proteins, NupC and NupG, from Escherichia coli: specific structural motifs necessary for the binding of ligands. , 2005, Organic & biomolecular chemistry.
[37] Reinhold Brückner,et al. Carbon catabolite repression in bacteria: choice of the carbon source and autoregulatory limitation of sugar utilization. , 2002, FEMS microbiology letters.
[38] E. Schneider. ABC transporters catalyzing carbohydrate uptake. , 2001, Research in microbiology.
[39] M. Reed. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface. , 2000, Postgraduate medicine.
[40] E. Bibi,et al. MdfA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition , 1997, Journal of bacteriology.
[41] S. Piscitelli,et al. Development of Resistance During Antimicrobial Therapy: A Review of Antibiotic Classes and Patient Characteristics in 173 Studies , 1995, Pharmacotherapy.
[42] K. Timmis,et al. The organization of the Pm promoter of the TOL plasmid reflects the structure of its cognate activator protein XylS , 1994, Molecular and General Genetics MGG.
[43] G. Sprenger,et al. Two open reading frames adjacent to the Escherichia coli K-12 transketolase (tkt) gene show high similarity to the mannitol phosphotransferase system enzymes from Escherichia coli and various gram-positive bacteria. , 1993, Biochimica et biophysica acta.
[44] M. Vaara,et al. Agents that increase the permeability of the outer membrane. , 1992, Microbiological reviews.
[45] T. Dougherty,et al. Tobramycin uptake in Escherichia coli is driven by either electrical potential or ATP , 1991, Journal of bacteriology.
[46] H. Nikaido,et al. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. , 1990, The Journal of biological chemistry.
[47] P. van de Heyning,et al. Aminoglycoside-induced ototoxicity. , 1990, Toxicology letters.
[48] J. Sugiyama,et al. Deletion mutants of the Escherichia coli K-12 mannitol permease: dissection of transport-phosphorylation, phospho-exchange, and mannitol-binding activities , 1989, Journal of bacteriology.
[49] P. Miller,et al. Bacterial uptake of aminoglycoside antibiotics. , 1987, Microbiological reviews.
[50] B. D. Davis,et al. Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[51] T. Beveridge,et al. Gentamicin interaction with Pseudomonas aeruginosa cell envelope , 1986, Antimicrobial Agents and Chemotherapy.
[52] G. Peters,et al. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. , 1984, Cancer research.
[53] B. Wallace,et al. Effect of growth rate on streptomycin accumulation by Escherichia coli and Bacillus megaterium. , 1984, Journal of general microbiology.
[54] R. Hancock. Aminoglycoside uptake and mode of action--with special reference to streptomycin and gentamicin. I. Antagonists and mutants. , 1981, The Journal of antimicrobial chemotherapy.
[55] Michael H. Miller,et al. Gentamicin Uptake in Wild-Type and Aminoglycoside-Resistant Small-Colony Mutants of Staphylococcus aureus , 1980, Antimicrobial Agents and Chemotherapy.
[56] S. Thorbjarnardóttir,et al. Mutations determining generalized resistance to aminoglycoside antibiotics in Escherichia coli , 1978, Molecular and General Genetics MGG.
[57] M. Wood,et al. Comparison of urinary excretion of tobramycin and gentamicin in adults. , 1976, The Journal of infectious diseases.
[58] L. Bryan,et al. Streptomycin Accumulation in Susceptible and Resistant Strains of Escherichia coli and Pseudomonas aeruginosa , 1976, Antimicrobial Agents and Chemotherapy.
[59] Seymour S. Cohen,et al. Interrelation Between Guanosine Tetraphosphate Accumulation, Ribonucleic Acid Synthesis, and Streptomycin Lethality in Escherichia coli CP78 , 1975, Antimicrobial Agents and Chemotherapy.
[60] W. Gilbert,et al. STREPTOMYCIN, SUPPRESSION, AND THE CODE. , 1964, Proceedings of the National Academy of Sciences of the United States of America.
[61] J. López-Novoa,et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. , 2011, Kidney international.
[62] S Falkow,et al. FACS-optimized mutants of the green fluorescent protein (GFP). , 1996, Gene.
[63] P. Sadowski,et al. Cleavage-dependent Ligation by the FLP Recombinase CHARACTERIZATION OF A MUTANT FLP PROTEIN WITH AN ALTERATION IN A CATALYTIC AMINO ACID* , 1995 .